Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Neoplasms 2Thyroid Cancer, Papillary 1Solid Cancers 1Lymphoma, Follicular 1Diabetes Mellitus, Type 2 1Carcinoma, Renal Cell 1Alzheimer Disease 1Adenocarcinoma, Follicular 1

Interventions

selpercatinib 3entrectinib 2tovorafenib 1pralsetinib 1motesanib diphosphate 1cabozantinib 1alectinib 1Thyrotropin Alfa 1Taxes 1Rosiglitazone 1Nivolumab 1Injections 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid Cancer, Papillary × Rosiglitazone × Clear all
NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡